{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:17:36Z","timestamp":1784207856186,"version":"3.55.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973730"],"award-info":[{"award-number":["81973730"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22010504300"],"award-info":[{"award-number":["22010504300"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010876","name":"Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010876","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.heliyon.2024.e28462","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T20:38:59Z","timestamp":1710967139000},"page":"e28462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Focus on pemphigus treatment publications: A bibliometric and visual analysis (1992\u20132022)"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4097-5319","authenticated-orcid":false,"given":"Xiujing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10201","key":"10.1016\/j.heliyon.2024.e28462_bib1","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28462_bib2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jaad.2020.11.075","article-title":"Intraepithelial autoimmune blistering dermatoses: clinical features and diagnosis","volume":"84","author":"Montagnon","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e28462_bib3","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/medicina57101080","article-title":"An Updated review of pemphigus diseases","volume":"57","author":"Malik","year":"2021","journal-title":"Medicina-Lithuania"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28462_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2021.100004","article-title":"Epidemiology of pemphigus","volume":"1","author":"Kridin","year":"2021","journal-title":"JID innovations"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28462_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3892\/etm.2021.10770","article-title":"Comprehensive review on the pathophysiology, clinical variants and management of pemphigus(Review)","volume":"22","author":"Costan","year":"2021","journal-title":"Exp. Ther. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28462_bib6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00403-014-1531-1","article-title":"Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid","volume":"307","author":"Alpsoy","year":"2015","journal-title":"Arch. Dermatol. Res."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e28462_bib7","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/1346-8138.14667","article-title":"Incidence and death rate of pemphigus vulgaris and pemphigus foliaceus in Korea: a nationwide, population-based study (2006-2015)","volume":"45","author":"Lee","year":"2018","journal-title":"J. Dermatol. (Tokyo)"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28462_bib8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clindermatol.2011.01.013","article-title":"Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis)","volume":"29","author":"Joly","year":"2011","journal-title":"Clin. Dermatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28462_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: overview, epidemiology, mortality, and comorbidities","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol. Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28462_bib10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/1346-8138.12286","article-title":"Epidemiology of pemphigus vulgaris in the Northeast China: a 10-year retrospective study","volume":"41","author":"Zhu","year":"2014","journal-title":"J. Dermatol. (Tokyo)"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28462_bib11","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1046\/j.1365-2133.2001.04228.x","article-title":"IgG, IgA and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris","volume":"144","author":"Spaeth","year":"2001","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28462_bib12","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1172\/JCI115781","article-title":"Human autoantibodies AGAINST DESMOPLAKINS IN paraneoplastic pemphigus","volume":"89","author":"Oursler","year":"1992","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28462_bib13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1590\/abd1806-4841.20199011","article-title":"Pemphigus vulgaris","volume":"94","author":"Porro","year":"2019","journal-title":"An. Bras. Dermatol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e28462_bib14","first-page":"1016","article-title":"Temporal course of avascular femoral head necrosis in patients with pemphigus vulgaris","volume":"14","author":"Balighi","year":"2016","journal-title":"Journal Der Deutschen Dermatologischen Gesellschaft"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e28462_bib15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-4632.2005.02218.x","article-title":"Twelve-year clinico-therapeutic experience in pemphigus: a retrospective study of 54 cases","volume":"44","author":"Mahajan","year":"2005","journal-title":"Int. J. Dermatol."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e28462_bib16","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted therapies for autoimmune bullous diseases: current Status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs"},{"issue":"3 PT B","key":"10.1016\/j.heliyon.2024.e28462_bib17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jid.2021.04.040","article-title":"Pemphigus and pemphigoid: from disease Mechanisms to Druggable pathways","volume":"142","author":"Ellebrecht","year":"2022","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28462_bib18","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/08820130902943097","article-title":"Involvement of T(H)1\/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris","volume":"38","author":"Satyam","year":"2009","journal-title":"Immunol. Invest."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28462_bib19","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10238-022-00855-8","article-title":"The emerging role of T cells in pemphigus vulgaris: a systematic review","volume":"23","author":"Araghi","year":"2023","journal-title":"Clin. Exp. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28462_bib20","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.3892\/mmr.2017.6422","article-title":"Increased miR-424-5p expression in peripheral blood mononuclear cells from patients with pemphigus","volume":"15","author":"Wang","year":"2017","journal-title":"Mol. Med. Rep."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28462_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00403-017-1790-8","article-title":"Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus","volume":"310","author":"Tavakolpour","year":"2018","journal-title":"Arch. Dermatol. Res."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e28462_bib22","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2174\/1389450120666190318121122","article-title":"The Use of naltrexone in Dermatology. Current Evidence and future directions","volume":"20","author":"Sikora","year":"2019","journal-title":"Curr. Drug Targets"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e28462_bib23","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1517\/13543784.13.8.1019","article-title":"Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy","volume":"13","author":"Ahmed","year":"2004","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28462_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/09546634.2019.1617831","article-title":"Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study","volume":"32","author":"Toosi","year":"2021","journal-title":"J. Dermatol. Treat."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28462_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archderm.135.1.54","article-title":"Mycophenolate is effective in the treatment of pemphigus vulgaris","volume":"135","author":"Enk","year":"1999","journal-title":"Arch. Dermatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28462_bib26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1046\/j.1468-3083.2002.00504.x","article-title":"Pemphigus vulgaris: a review of treatment over a 19-year period","volume":"16","author":"Ljubojevic","year":"2002","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28462_bib27","first-page":"13","article-title":"Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme)","volume":"130","author":"Corven","year":"2003","journal-title":"Annales De Dermatologie Et De Venereologie"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28462_bib28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/09546630701287324","article-title":"Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone","volume":"18","author":"Scheinfeld","year":"2007","journal-title":"J. Dermatol. Treat."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28462_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15264","article-title":"A review of reported infectious events following rituximab therapy in pemphigus patients","volume":"35","author":"Shahrigharahkoshan","year":"2022","journal-title":"Dermatol. Ther."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e28462_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130141","article-title":"Stabilization of desmoglein-2 binding rescues arrhythmia in arrhythmogenic cardiomyopathy","volume":"5","author":"Schinner","year":"2020","journal-title":"Jci Insight"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e28462_bib31","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/08916930600972040","article-title":"Immunoadsorption in pemphigus","volume":"39","author":"Eming","year":"2006","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28462_bib32","first-page":"211","article-title":"New and innovative interventions in the management of pemphigus","volume":"146","author":"Frydman","year":"2011","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"10.1016\/j.heliyon.2024.e28462_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.583354","article-title":"Treatment of autoimmune bullous diseases during pregnancy and Lactation: a review focusing on pemphigus and pemphigoid Gestationis","volume":"11","author":"Genovese","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28462_bib34","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3171\/2015.7.JNS151647","article-title":"Bibliometrics","volume":"124","author":"Klimo","year":"2016","journal-title":"J. Neurosurg."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28462_bib35","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","article-title":"Bibliometrix: an R-tool for comprehensive science mapping analysis","volume":"11","author":"Aria","year":"2017","journal-title":"Journal of Informetrics"},{"key":"10.1016\/j.heliyon.2024.e28462_bib36","article-title":"Bibliometric and visual analysis of nocturnal enuresis from 1982 to 2022","volume":"10","author":"Li","year":"2022","journal-title":"Frontiers in Pediatrics"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28462_bib37","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28462_bib38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/asi.4630240406","article-title":"Co-Citation in the Scientific literature: a new measure of the relationship between two documents","volume":"24","author":"Henry","year":"1973","journal-title":"J. Am. Soc. Inf. Sci."},{"issue":"10083","key":"10.1016\/j.heliyon.2024.e28462_bib39","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e28462_bib40","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28462_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: Recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28462_bib42","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/01.AOG.0000185258.74177.91","article-title":"Involvement of the female genital tract in pemphigus vulgaris","volume":"106","author":"Malik","year":"2005","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28462_bib43","article-title":"Diagnosis and clinical features of pemphigus vulgaris","volume":"32","author":"Venugopal","year":"2012","journal-title":"Immunol. Allergy Clin."},{"key":"10.1016\/j.heliyon.2024.e28462_bib44","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fimmu.2018.00136","article-title":"Pemphigus-A disease of desmosome dysfunction caused by multiple mechanisms","volume":"9","author":"Spindler","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28462_bib45","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0190-9622(96)80066-1","article-title":"Influence of treatment on the clinical course of pemphigus vulgaris","volume":"34","author":"Carson","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28462_bib46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/jdv.12772","article-title":"Pemphigus. S2 guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"29","author":"Hertl","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28462_bib47","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1590\/abd1806-4841.2019940206","article-title":"Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology","volume":"94","author":"Porro","year":"2019","journal-title":"An. Bras. Dermatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28462_bib48","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1468-3083.2010.03753.x","article-title":"High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi-centre, comparative study","volume":"25","author":"Chaidemenos","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28462_bib49","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0190-9622(08)81506-X","article-title":"The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus - preliminary-study","volume":"30","author":"Lapidoth","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28462_bib50","first-page":"73","article-title":"Pemphigus foliaceus complicated by disseminated cutaneous herpes simplex virus infection in an elderly man","volume":"21","author":"Cheng","year":"2013","journal-title":"Hong Kong Journal of Dermatology & Venereology"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28462_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.det.2011.03.012","article-title":"Diagnosis and clinical features of pemphigus foliaceus","volume":"29","author":"James","year":"2011","journal-title":"Dermatol. Clin."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28462_bib52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.oraloncology.2003.09.020","article-title":"Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations","volume":"40","author":"Kaplan","year":"2004","journal-title":"Oral Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e28462_bib53","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1346-8138.2007.00347.x","article-title":"Paraneoplastic pemphigus presenting as erythrodermic lichenoid dermatitis with concomitant features of pemphigus foliaceus","volume":"34","author":"Fukumoto","year":"2007","journal-title":"J. Dermatol. (Tokyo)"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28462_bib54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1087-0024.2004.00832.x","article-title":"Paraneoplastic pemphigus","volume":"9","author":"Anhalt","year":"2004","journal-title":"J. Invest. Dermatol. Symp. Proc."},{"key":"10.1016\/j.heliyon.2024.e28462_bib55","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3389\/fimmu.2019.01259","article-title":"Paraneoplastic pemphigus: paraneoplastic autoimmune disease of the skin and mucosa","volume":"10","author":"Kim","year":"2019","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28462_bib56","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/jdv.18931","article-title":"S2k guidelines on the management of paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"37","author":"Antiga","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28462_bib57","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00432-010-0874-z","article-title":"Improved outcomes after complete resection of underlying tumors for patients with paraneoplastic pemphigus: a single-center experience of 22 cases","volume":"137","author":"Zhang","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28462_bib58","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/1346-8138.16653","article-title":"B-cell targeted therapy of pemphigus","volume":"50","author":"Yamagami","year":"2023","journal-title":"J. Dermatol. (Tokyo)"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e28462_bib59","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1346-8138.2005.tb00801.x","article-title":"Mycophenolate mofetil as an adjuvant therapy for classic and endemic pemphigus foliaceus","volume":"32","author":"Kawashita","year":"2005","journal-title":"J. Dermatol. (Tokyo)"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28462_bib60","first-page":"159","article-title":"Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent","volume":"18","author":"Esmaili","year":"2008","journal-title":"Eur. J. Dermatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28462_bib61","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1067\/mjd.2001.114746","article-title":"Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent","volume":"45","author":"Megahed","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28462_bib62","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/09546634.2014.880395","article-title":"Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus","volume":"26","author":"Doukaki","year":"2015","journal-title":"J. Dermatol. Treat."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28462_bib63","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1365-2133.2003.05269.x","article-title":"An evaluation of the usefulness of mycophenolate mofetil in pemphigus","volume":"149","author":"Powell","year":"2003","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28462_bib64","first-page":"23","article-title":"Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris","volume":"129","author":"Chams-Davatchi","year":"2002","journal-title":"Annales De Dermatologie Et De Venereologie"},{"issue":"24","key":"10.1016\/j.heliyon.2024.e28462_bib65","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28462_bib66","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/1744-9987.12555","article-title":"Selective plasma exchange for the removal of pemphigus autoantibodies, fibrinogen, and factor XIII in pemphigus vulgaris","volume":"21","author":"Miyamoto","year":"2017","journal-title":"Ther. Apher. Dial."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28462_bib67","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4103\/0019-5154.160509","article-title":"Therapeutic plasma exchange-A new dawn in the treatment of pemphigus vulgaris","volume":"60","author":"Kumar","year":"2015","journal-title":"Indian J. Dermatol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28462_bib68","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-3083.2010.03703.x","article-title":"The role of therapeutic plasma exchange in pemphigus vulgaris","volume":"25","author":"Sagi","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28462_bib69","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1067\/mjd.2000.108366","article-title":"Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris","volume":"43","author":"Engineer","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28462_bib70","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40257-020-00544-w","article-title":"Novel therapies for pemphigus vulgaris","volume":"21","author":"Altman","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e28462_bib71","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0151-9638(04)93805-7","article-title":"Treatment of pemphigus with intravenous immunoglobulin","volume":"131","author":"Levy","year":"2004","journal-title":"Annales De Dermatologie Et De Venereologie"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28462_bib72","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(89)80148-3","article-title":"High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid","volume":"20","author":"Tappeiner","year":"1989","journal-title":"J. Am. Acad. Dermatol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e28462_bib73","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1346-8138.12280","article-title":"Four mild but refractory cases of pemphigus foliaceus successfully treated with intravenous immunoglobulin","volume":"40","author":"Kawakami","year":"2013","journal-title":"J. Dermatol. (Tokyo)"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28462_bib74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1590\/S0365-05962011000700035","article-title":"Refractory endemic pemphigus foliaceous in adolescence successfully treated with intravenous immunoglobulin","volume":"86","author":"Teixeira","year":"2011","journal-title":"An. Bras. Dermatol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28462_bib75","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/09273940590951025","article-title":"Eyelid skin involvement in pemphigus foliaceus","volume":"13","author":"Daoud","year":"2005","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28462_bib76","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1525-1470.2008.00808.x","article-title":"Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulin therapy","volume":"26","author":"Asarch","year":"2009","journal-title":"Pediatr. Dermatol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28462_bib77","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2340\/00015555-1471","article-title":"Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and No serious adverse events","volume":"93","author":"Seidling","year":"2013","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.heliyon.2024.e28462_bib78","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fmed.2018.00218","article-title":"The evolving story of autoantibodies in pemphigus vulgaris: development of the \"super compensation hypothesis\"","volume":"5","author":"Sinha","year":"2018","journal-title":"Front. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28462_bib79","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jaad.2016.11.039","article-title":"Correlation of antimuscarinic acetylcholine receptor antibody titers and antidesmoglein antibody titers with the severity of disease in patients with pemphigus","volume":"76","author":"Lakshmi","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28462_bib80","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/ijd.16363","article-title":"Elevated serum level of B-cell activating factor (BAFF) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B-cell depletion therapies combined with anti-BAFF agents","volume":"62","author":"Daneshvar","year":"2023","journal-title":"Int. J. Dermatol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28462_bib81","doi-asserted-by":"crossref","first-page":"E369","DOI":"10.1590\/1678-4685-gmb-2019-0369","article-title":"Beyond the HLA polymorphism: a complex pattern of genetic susceptibility to pemphigus","volume":"43","author":"Petzl-Erler","year":"2020","journal-title":"Genet. Mol. Biol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28462_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2016.08.039","article-title":"Interventional treatments for Hailey-Hailey disease","volume":"76","author":"Farahnik","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28462_bib83","doi-asserted-by":"crossref","first-page":"XXII","DOI":"10.1111\/j.0022-202X.2004.23482.x","article-title":"Yeast researchers consider Hailey-Hailey disease","volume":"123","author":"Mauro","year":"2004","journal-title":"J. Invest. Dermatol."},{"issue":"20","key":"10.1016\/j.heliyon.2024.e28462_bib84","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1007\/s00018-017-2544-7","article-title":"The role of the ATP2C1 gene in Hailey-Hailey disease","volume":"74","author":"Deng","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28462_bib85","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40257-019-00477-z","article-title":"Hailey-hailey disease: an update review with a focus on treatment data","volume":"21","author":"Ben Lagha","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28462_bib86","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/bjd.18861","article-title":"Improvement of Hailey-Hailey disease with low-dose naltrexone","volume":"182","author":"Jasans-Barcelo","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28462_bib87","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1142\/S0192415X20500421","article-title":"Chrysanthemum indicum L.: A comprehensive review of its botany, phytochemistry and pharmacology","volume":"48","author":"Shao","year":"2020","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.heliyon.2024.e28462_bib88","article-title":"Beneficial effects and safety of corticosteroids combined with traditional Chinese medicine for pemphigus: a systematic review","volume":"2015","author":"Zhou","year":"2015","journal-title":"Evid. base Compl. Alternative Med."},{"key":"10.1016\/j.heliyon.2024.e28462_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.594486","article-title":"Complementary Chinese herbal medicine therapy improves survival in patients with pemphigus: a retrospective study from a Taiwan-based registry","volume":"11","author":"Wu","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28462_bib90","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/imt-2017-0104","article-title":"Rituximab in pemphigus","volume":"10","author":"Hebert","year":"2018","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28462_bib91","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/1096-8652(200102)66:2<142::AID-AJH1032>3.0.CO;2-0","article-title":"Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL","volume":"66","author":"Heizmann","year":"2001","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28462_bib92","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/00099228221140801","article-title":"Successful treatment of recalcitrant pediatric pemphigus vulgaris with rituximab","volume":"62","author":"Santiago-Vazquez","year":"2023","journal-title":"Clin. Pediatr."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28462_bib93","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4103\/ijd.ijd_169_22","article-title":"Experience of rituximab therapy in pemphigus: a three-year retrospective study from a Sub-Himalayan State","volume":"67","author":"Verma","year":"2022","journal-title":"Indian J. Dermatol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e28462_bib94","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15902","article-title":"Applicability of glucocorticoid toxicity index in pemphigus: comparison between two groups of rituximab-treated and rituximab-naive patients","volume":"35","author":"Mazaherpour","year":"2022","journal-title":"Dermatol. Ther."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28462_bib95","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12016-021-08882-1","article-title":"Comparison of guidelines for management of pemphigus: a review of systemic corticosteroids, rituximab, and other immunosuppressive therapies","volume":"61","author":"Zhao","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e28462_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2021.01.031","article-title":"Rituximab and corticosteroid effect on desmoglein-specific B cells and desmoglein-specific T follicular helper cells in pemphigus","volume":"141","author":"Maho-Vaillant","year":"2021","journal-title":"J. Invest. Dermatol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e28462_bib97","doi-asserted-by":"crossref","first-page":"E350","DOI":"10.1111\/jdv.14144","article-title":"Fatal infection of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab","volume":"31","author":"Wei","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28462_bib98","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1684\/ejd.2018.3373","article-title":"Pneumocystis jirovecii pneumonia infection in pemphigus patients treated with rituximab: an observational nationwide epidemiological study in Taiwan","volume":"28","author":"Wei","year":"2018","journal-title":"Eur. J. Dermatol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28462_bib99","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/ijdvl.IJDVL_1078_14","article-title":"Low-dose rituximab as an adjuvant therapy in pemphigus","volume":"83","author":"Gupta","year":"2017","journal-title":"Indian J. Dermatol., Venereol. Leprol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28462_bib100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2022.5182","article-title":"Association of rituximab with risk of long-term cardiovascular and metabolic outcomes in patients with pemphigus","volume":"159","author":"Kridin","year":"2023","journal-title":"Jama Dermatology"},{"key":"10.1016\/j.heliyon.2024.e28462_bib101","series-title":"Contemporary Challenges in Autoimmunity","first-page":"683","article-title":"Rituximab in severe pemphigus","author":"Schmidt","year":"2009"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e28462_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2022.09.160","article-title":"Rituximab in the treatment of pemphigus: a single-center Moroccan analysis of 43 cases","volume":"142","author":"Mezni","year":"2022","journal-title":"J. Invest. Dermatol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024044931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024044931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:57:05Z","timestamp":1784206625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024044931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":102,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2405844024044931"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28462","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Focus on pemphigus treatment publications: A bibliometric and visual analysis (1992\u20132022)","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e28462"}}